

Communicable Diseases and Immunization Service 655 West 12th Avenue Vancouver, BC V5Z 4R4

Tel 604.707.2548 Fax 604.707.2515 www.bccdc.ca

Date: July 2, 2021 Administrative Circular: 2021:27

**ATTN:** Medical Health Officers and Branch Offices

Public Health Nursing Administrators and Assistant Administrators

Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Part 4 – Biological Products

# Part 4 - Biological Products

## **COVID-19 Vaccines**

## COVID-19 mRNA Vaccine BNT162b2 (Pfizer)

The product page has been revised as follows:

#### Precautions:

A precaution has been added to indicate that individuals who experience myocarditis or pericarditis following the first dose of vaccine with no other cause identified, should defer the 2<sup>nd</sup> dose until further information about the risk of recurrence is available. While the majority of the risk appears to be associated with the 2<sup>nd</sup> dose of mRNA vaccine (Pfizer or Moderna), additional information about the association, causal mechanism, and risk of recurrence with 2<sup>nd</sup> dose in those who experience this event after the 1<sup>st</sup> dose is expected to accumulate over time.

Please remove page numbers: 1-5 dated June 25, 2021 Please add new page numbers: 1-6 dated July 2, 2021

#### **COVID-19 mRNA Vaccine mRNA-1273 (Moderna)**

The product page has been revised as follows:

#### Precautions:

A precaution has been added to indicate that individuals who experience myocarditis or pericarditis following the first dose of vaccine with no other cause identified, should defer the 2<sup>nd</sup> dose until further information about the risk of recurrence is available. While the majority of the risk appears to be associated with the 2<sup>nd</sup> dose of mRNA vaccine (Pfizer or Moderna), additional information





# BC Centre for Disease Control Provincial Health Services Authority

about the association, causal mechanism, and risk of recurrence with 2<sup>nd</sup> dose in those who experience this event after the 1<sup>st</sup> dose is expected to accumulate over time.

Please remove page numbers: 1-4 dated June 25, 2021 Please add new page numbers: 1-4 dated July 2, 2021

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: <a href="mailto:stephanie.meier@bccdc.ca">stephanie.meier@bccdc.ca</a>).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM

**Medical Director** 

Communicable Diseases & Immunization Service

**BC** Centre for Disease Control

With bans

pc:

Provincial Health Officer

Dr. Bonnie Henry

Dr. Reka Gustafson

Vice President, Public Health &

Wellness, PHSA & Deputy Provincial

**Health Officer** 

Deputy Provincial Health Officer

Dr. Martin Lavoie

BC Ministry of Health, Population &

Public Health Division:

Brian Sagar

Senior Director Communicable

Disease, Population and Public Health

Division

Bernard Achampong

Executive Director,

Public Health, Planning and Prevention,

Population and Public Health Division



